Targeted Disruption of Plasmodium Falciparum Cysteine Protease, Falcipain 1, Reduces Oocyst Production, Not Erythrocytic Stage Growth
Overview
Molecular Biology
Affiliations
Cysteine proteases are currently targets for drug development in a number of parasitic diseases, including malaria. In Plasmodium falciparum, the parasite responsible for the most virulent form of human malaria, there are four members of the cathepsin L-like family of cysteine proteases. Three of these (falcipains 2A, 2B and 3) are thought to be primarily involved in haemoglobin digestion, whereas falcipain 1 has recently been linked to erythrocyte invasion. Neither their expression nor their role in P. falciparum gametocytogenesis, which is required for malaria transmission, has been evaluated. In this study, RNA transcripts for the falcipain family members were identified as the parasite developed through all five stages of gametocytogenesis. Falcipain 1 transcript was upregulated in gametocytes, while levels of falcipain 2A/2B decreased in late-stage gametocytes and gametes. To evaluate the function of falcipain 1, the gene was disrupted, and clones from independent transformations were isolated. The asexual growth of the falcipain 1 minus clones was not overtly affected, and they produced morphologically normal gametocytes and gametes. However, when falcipain 1 minus parasites were fed to a mosquito, oocyst production was reduced by 70-90%, suggesting an important role for falcipain 1 during parasite development in the mosquito midgut.
Malaria parasite cysteine and aspartic proteases as key drug targets for antimalarial therapy.
Adeoye A, Lobb K J Mol Model. 2025; 31(3):78.
PMID: 39920505 DOI: 10.1007/s00894-025-06303-0.
Gonzalez J, Salas-Sarduy E, Alvarez L, Valiente P, Arni R, Pascutti P Curr Med Chem. 2023; 31(16):2234-2263.
PMID: 37711130 DOI: 10.2174/0929867331666230913165219.
The Impact of Activity-Based Protein Profiling in Malaria Drug Discovery.
Carvalho L, Bernardes G ChemMedChem. 2022; 17(14):e202200174.
PMID: 35506504 PMC: 9401580. DOI: 10.1002/cmdc.202200174.
Musyoka T, Njuguna J, Tastan Bishop O Malar J. 2019; 18(1):159.
PMID: 31053072 PMC: 6500056. DOI: 10.1186/s12936-019-2790-2.
Structural Insights Into Key Proteases as Therapeutic Drug Targets.
Mishra M, Singh V, Singh S Front Microbiol. 2019; 10:394.
PMID: 30891019 PMC: 6411711. DOI: 10.3389/fmicb.2019.00394.